Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Quidel's Trichomonas Assay

NEW YORK (GenomeWeb) – Quidel today announced that the US Food and Drug Administration has cleared the company's AmpliVue Trichomonas Assay for marketing. 

The assay detects nucleic acids isolated from vaginal swab specimens obtained by clinicians from symptomatic and asymptomatic female patients. It runs on Quidel's AmpliVue handheld molecular diagnostic device and does not require upfront DNA extraction. Quidel said the assay generates results in about 50 minutes. 

The trichomonas assay is the sixth to be cleared by the FDA for the AmpliVue device, following earlier clearances for Clostridium difficile, Group A Streptococcus, Group B Streptococcus, Bordetella pertussis, and herpes simplex viruses 1 and 2. 

Citing statistics from the US Centers for Disease Control and Prevention, Quidel said about 3.7 million people in the US have trichomoniasis, the sexually transmitted disease attributable to infection by the Trichomonas vaginalis parasite. 

"We believe that our test will play a critical role in quickly diagnosing this disease, creating opportunities for patient treatment and thereby limiting its spread," Quidel President and CEO Douglas Bryant said in a statement. 

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.